Avalo Therapeutics, Inc. (AVTX) shareholders
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.90%), Michael Kramarz (9.90%) and 1 more | 5,721,109 | 9.90% | 13G (passive) | Jun 11, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (9.80%) | 5,250,181 | 9.80% | 13G (passive) amendment | Sep 30, 2026 |
| Deep Track Capital, LP Joint filing with David Kroin (6.87%), Deep Track Biotechnology Master Fund, Ltd. (6.87%) | 3,610,000 | 6.87% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with Peter Kolchinsky (6.30%), RA Capital Healthcare Fund, L.P. (6.30%) and 1 more | 3,483,099 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,415,731 | 6.50% | 13G (passive) | Jun 30, 2026 |
| Caligan Partners LP Joint filing with David Johnson (5.90%) | 3,163,866 | 5.90% | 13G (passive) amendment | Jun 30, 2026 |
| David Kroin Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.81%), Deep Track Capital, LP (5.81%) | 3,055,027 | 5.81% | 13G (passive) | May 22, 2026 |
| TCG Crossover Fund II, L.P. Joint filing with Chen Yu (7.90%), TCG Crossover GP II, LLC (7.90%) | 3,017,120 | 7.90% | 13G (passive) | May 5, 2026 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (5.50%) | 2,900,000 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| Ortav Yehudai Joint filing with Trails Edge Biotechnology Master Fund, LP (5.20%), Trails Edge Capital Partners, LP (5.20%) | 2,803,761 | 5.20% | 13G (passive) | Oct 22, 2026 |
| Lampert Mark N Joint filing with Bvf Inc/Il (5.30%), Bvf Partners L P/Il (5.30%) | 2,801,545 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (5.20%), Steven A. Cohen (5.20%) | 2,710,817 | 5.20% | 13G (passive) | May 22, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 1,904,257 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| David Johnson Joint filing with Caligan Partners LP (7.20%) | 1,635,023 | 7.20% | 13G (passive) amendment | Mar 31, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 1,458,151 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (5.75%) | 1,410,000 | 5.75% | 13G (passive) | Mar 31, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), RA Capital Healthcare Fund, L.P. (9.90%) and 1 more | 1,386,167 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Logos Global Master Fund LP Joint filing with Arsani William (5.60%), Logos GP LLC (5.60%) and 2 more | 1,285,000 | 5.60% | 13G (passive) | Mar 26, 2026 |
| Affinity Asset Advisors, LLC Joint filing with Michael Cho (5.70%) | 1,051,054 | 5.70% | 13G (passive) amendment | Jan 22, 2026 |
| Millennium Management LLC Joint filing with Israel A. Englander (5.00%), Millennium Group Management LLC (5.00%) | 934,429 | 5.00% | 13G (passive) | Feb 17, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 5,100,216 | 9.51% | $94.25M | +2,220,735 | 0.00% |
| BlackRock, Inc. | 4,365,553 | 8.14% | $80.68M | +4,038,471 | 0.00% |
| Nantahala Capital Management, LLC | 3,724,500 | 6.94% | $68.83M | +2,489,500 | 1.14% |
| Deep Track Capital, LP | 3,610,000 | 6.73% | $66.71M | New | 0.97% |
| Caligan Partners LP | 3,163,866 | 5.90% | $58.47M | +1,528,843 | 2.75% |
| TCG Crossover Management, LLC | 3,017,120 | 5.63% | $55.76M | +2,278,737 | 1.34% |
| Affinity Asset Advisors, LLC | 2,900,000 | 5.41% | $53.59M | +1,559,160 | 2.42% |
| State Street Corp | 2,889,287 | 5.39% | $53.39M | +2,817,633 | 0.00% |
| Farallon Capital Management LLC | 2,498,000 | 4.66% | $46.16M | +1,582,000 | 0.21% |
| Point72 Asset Management, L.P. | 2,387,026 | 4.45% | $44.11M | +1,470,884 | 0.05% |
| Avoro Capital Advisors LLC | 2,333,333 | 4.35% | $43.12M | +923,333 | 0.39% |
| Vanguard Capital Management LLC | 2,264,246 | 4.22% | $41.84M | +1,544,552 | 0.00% |
| Bvf Inc/Il | 2,075,545 | 3.87% | $38.36M | +442,700 | 0.98% |
| Bank Of America Corp /De/ | 1,913,829 | 3.57% | $35.37M | +1,270,829 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 1,729,000 | 3.22% | $31.95M | +875,000 | 0.04% |
| Soleus Capital Management, L.P. | 1,654,978 | 3.09% | $30.58M | +1,213,000 | 1.05% |
| Braidwell LP | 1,629,182 | 3.04% | $30.11M | New | 1.11% |
| Price T Rowe Associates Inc /Md/ | 1,311,715 | 2.45% | $24.24M | New | 0.00% |
| Alliancebernstein L.P. | 1,260,689 | 2.35% | $23.30M | New | 0.01% |
| UBS Group AG | 1,209,059 | 2.25% | $22.34M | +67,079 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 126 | 73M | 100.0% | 56 / 47 | 15 / 27 | 50M | 8M |
| Q1 2026 | 97 | 31M | 58.2% | 33 / 31 | 19 / 19 | 16M | 4M |
| Q4 2025 | 84 | 20M | 37.1% | 33 / 28 | 13 / 15 | 7M | 2M |
| Q3 2025 | 66 | 15M | 28.6% | 32 / 15 | 8 / 2 | 8M | 1M |
| Q2 2025 | 36 | 8M | 14.6% | 4 / 9 | 12 / 2 | 1M | 1M |
| Q1 2025 | 34 | 8M | 15.4% | 5 / 11 | 4 / 4 | 2M | 1M |
| Q4 2024 | 33 | 8M | 14.0% | 9 / 8 | 4 / 5 | 2M | 1M |
| Q3 2024 | 29 | 7M | 12.4% | 11 / 3 | 1 / 2 | 6M | 0M |
| Q2 2024 | 21 | 1M | 1.4% | 7 / 4 | 4 / 4 | 1M | 0M |
| Q1 2024 | 18 | 0M | 0.2% | 8 / 4 | 3 / 2 | 0M | 0M |
| Q4 2023 | 12 | 0M | 0.0% | 12 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
100 funds held AVTX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AVTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,029,492 | 3.78% | $37.51M | 0.35% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,675,498 | 3.12% | $30.96M | 0.00% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,211,600 | 2.26% | $22.11M | 0.30% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 1,093,326 | 2.04% | $20.20M | 0.02% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 695,600 | 1.30% | $12.69M | 0.27% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 639,700 | 1.19% | $11.67M | 0.53% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 537,241 | 1.00% | $9.93M | 0.01% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 486,556 | 0.91% | $8.99M | 0.29% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 471,822 | 0.88% | $8.72M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 457,313 | 0.85% | $8.35M | 0.02% | Jul 31, 2026 |
| Fidelity Small Cap Discovery Fund | 384,671 | 0.72% | $7.02M | 0.31% | Jul 31, 2026 |
| Fidelity Series Small Cap Discovery Fund | 330,470 | 0.62% | $6.03M | 0.31% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 299,585 | 0.56% | $4.78M | 0.08% | May 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 287,663 | 0.54% | $5.32M | 0.04% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 212,200 | 0.40% | $3.87M | 0.25% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Garry Arthur Neil | Chief Executive Officer, Director | 190,314 | 0.35% | May 26, 2026 |
| Christopher Ryan Sullivan | Chief Financial Officer | 39,900 | 0.07% | Sep 18, 2026 |
| Mittie Doyle | Chief Medical Officer | 51,776 | 0.10% | Sep 1, 2026 |
| Jennifer Riley | Chief Strategy Officer | 37,041 | 0.07% | Aug 12, 2026 |
| Paul Varki | Chief Legal Officer | 32,576 | 0.06% | Jun 12, 2026 |
| Taylor Boyd | Chief Business Officer | – | – | Mar 2, 2026 |
| Rita Jain | Director | – | – | Oct 2, 2026 |
| Ron M. Philip | Director | – | – | Oct 2, 2026 |
| Kevin Robert Lind | Director | – | – | Oct 2, 2026 |
| Samantha Truex | Director | 6,333 | 0.01% | Jun 4, 2026 |
| Gilla Kaplan | Director | 6,333 | 0.01% | Jun 4, 2026 |
| Aaron Kantoff | Director | 6,333 | 0.01% | Jun 4, 2026 |
| Michael Thomas Heffernan | Director | – | – | Jun 4, 2026 |
| Mitchell Chan | Director | 3,166 | 0.01% | May 7, 2026 |
| Jonathan Goldman | Director | 3,166 | 0.01% | Mar 31, 2026 |
| June Sherie Almenoff | Director | 4,167 | 0.01% | Jun 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher Ryan Sullivan Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −12,394 | $16.33 | $202.39K | 39,900 |
| Christopher Ryan Sullivan Chief Financial Officer | Sep 16, 2026 | Option exercise | +12,394 | $9.88 | $122.45K | 52,294 |
| Christopher Ryan Sullivan Chief Financial Officer | Sep 10, 2026 | Sale(10b5-1 plan) | −10,185 | $17.62 | $179.46K | 39,900 |
| Christopher Ryan Sullivan Chief Financial Officer | Sep 10, 2026 | Option exercise | +10,185 | $8.04 | $81.89K | 50,085 |
| Mittie Doyle Chief Medical Officer | Aug 28, 2026 | Sale(10b5-1 plan) | −679 | $20.00 | $13.58K | 51,776 |
| Mittie Doyle Chief Medical Officer | Aug 28, 2026 | Option exercise | +679 | $8.04 | $5.46K | 52,455 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 18, 2026 | Option exercise | +31,031 | $9.88 | $306.59K | 70,931 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −31,031 | $20.05 | $622.17K | 39,900 |
| Mittie Doyle Chief Medical Officer | Aug 17, 2026 | Option exercise | +1,000 | $12.65 | $12.65K | 52,776 |
| Mittie Doyle Chief Medical Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −1,000 | $20.00 | $20.00K | 51,776 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 17, 2026 | Option exercise | +37,945 | $9.88 | $374.90K | 78,718 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 17, 2026 | Option exercise | +2,876 | $9.88 | $28.41K | 81,594 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −37,945 | $19.85 | $753.21K | 43,649 |
| Christopher Ryan Sullivan Chief Financial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −3,749 | $19.94 | $74.76K | 39,900 |
| Jennifer Riley Chief Strategy Officer | Aug 11, 2026 | Sale | −2,655 | $19.59 | $52.01K | 37,041 |
| Mittie Doyle Chief Medical Officer | Aug 10, 2026 | Sale(10b5-1 plan) | −679 | $20.00 | $13.58K | 51,776 |
| Mittie Doyle Chief Medical Officer | Aug 10, 2026 | Option exercise | +679 | $8.04 | $5.46K | 52,455 |
| Mittie Doyle Chief Medical Officer | Jul 27, 2026 | Option exercise | +1,000 | $12.65 | $12.65K | 52,776 |
| Mittie Doyle Chief Medical Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −1,000 | $20.00 | $20.00K | 51,776 |
| Mittie Doyle Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −4,654 | $20.00 | $93.08K | 51,776 |
| Mittie Doyle Chief Medical Officer | Jun 30, 2026 | Option exercise | +1,779 | $8.04 | $14.30K | 56,430 |
| Mittie Doyle Chief Medical Officer | Jun 30, 2026 | Option exercise | +2,875 | $12.65 | $36.37K | 54,651 |
| Mittie Doyle Chief Medical Officer | Jun 23, 2026 | Option exercise | +1,450 | $8.04 | $11.66K | 53,226 |
| Mittie Doyle Chief Medical Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −1,450 | $18.00 | $26.10K | 51,776 |
| Mittie Doyle Chief Medical Officer | Jun 10, 2026 | Tax withholding | −1,084 | $13.10 | $14.20K | 51,776 |
| Jennifer Riley Chief Strategy Officer | Jun 10, 2026 | Tax withholding | −588 | $13.10 | $7.70K | 39,696 |
| Paul Varki Chief Legal Officer | Jun 10, 2026 | Tax withholding | −1,081 | $13.10 | $14.16K | 32,576 |
| Christopher Ryan Sullivan Chief Financial Officer | Jun 10, 2026 | Tax withholding | −138 | $13.10 | $1.81K | 40,773 |
| Mittie Doyle Chief Medical Officer | May 28, 2026 | Sale(10b5-1 plan) | −679 | $16.00 | $10.86K | 47,122 |
| Mittie Doyle Chief Medical Officer | May 28, 2026 | Option exercise | +679 | $8.04 | $5.46K | 47,801 |
| Paul Varki Chief Legal Officer | May 21, 2026 | Award | +24,300 | – | – | 27,934 |
| Garry Arthur Neil Chief Executive Officer, Director | May 21, 2026 | Award | +100,200 | – | – | 190,314 |
| Jennifer Riley Chief Strategy Officer | May 21, 2026 | Award | +34,200 | – | – | 36,855 |
| Christopher Ryan Sullivan Chief Financial Officer | May 21, 2026 | Award | +39,900 | – | – | 40,323 |
| Mittie Doyle Chief Medical Officer | May 21, 2026 | Award | +43,500 | – | – | 47,122 |
| Mittie Doyle Chief Medical Officer | May 15, 2026 | Option exercise | +3,000 | $12.65 | $37.95K | 6,622 |
| Mittie Doyle Chief Medical Officer | May 15, 2026 | Sale(10b5-1 plan) | −3,000 | $18.76 | $56.28K | 3,622 |
| Christopher Ryan Sullivan Chief Financial Officer | May 7, 2026 | Option exercise | +18,606 | $9.88 | $183.83K | 19,029 |
| Christopher Ryan Sullivan Chief Financial Officer | May 7, 2026 | Sale(10b5-1 plan) | −18,606 | $24.12 | $448.78K | 423 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Sale(10b5-1 plan) | −22,839 | $21.22 | $484.64K | 13,287 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Option exercise | +62,500 | $13.43 | $839.38K | 66,134 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Sale(10b5-1 plan) | −400 | $23.71 | $9.48K | 3,634 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Sale(10b5-1 plan) | −9,253 | $22.70 | $210.04K | 4,034 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Sale(10b5-1 plan) | −5,196 | $19.78 | $102.78K | 36,126 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Sale(10b5-1 plan) | −37,375 | $18.91 | $706.76K | 41,322 |
| Paul Varki Chief Legal Officer | May 6, 2026 | Option exercise | +12,563 | $8.04 | $101.01K | 78,697 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Option exercise | +28,650 | $8.04 | $230.35K | 110,177 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Option exercise | +77,905 | $12.65 | $985.50K | 81,527 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Sale(10b5-1 plan) | −10,058 | $22.88 | $230.13K | 3,622 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Sale(10b5-1 plan) | −27,538 | $18.03 | $496.51K | 82,639 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Sale(10b5-1 plan) | −5,000 | $19.65 | $98.25K | 77,639 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Sale(10b5-1 plan) | −44,944 | $21.20 | $952.81K | 32,695 |
| Mittie Doyle Chief Medical Officer | May 6, 2026 | Sale(10b5-1 plan) | −19,015 | $22.41 | $426.13K | 13,680 |
| Mitchell Chan Director | May 6, 2026 | Sale(10b5-1 plan) | −3,167 | $22.88 | $72.46K | 3,166 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Option exercise | +47,000 | $8.04 | $377.88K | 47,423 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Sale(10b5-1 plan) | −13,834 | $18.55 | $256.62K | 33,589 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Sale(10b5-1 plan) | −8,900 | $22.57 | $200.87K | 423 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Sale(10b5-1 plan) | −12,347 | $19.28 | $238.05K | 21,242 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Sale(10b5-1 plan) | −2,700 | $20.76 | $56.05K | 18,542 |
| Christopher Ryan Sullivan Chief Financial Officer | May 6, 2026 | Sale(10b5-1 plan) | −9,219 | $21.37 | $197.01K | 9,323 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avalo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,952 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher Ryan Sullivan Officer | Aug 18, 2026 | 31,031 | $622.22K | Aug 18, 2026 | Exercise of Options Under a Registered Plan |
| Christopher Ryan Sullivan Officer | Aug 17, 2026 | 3,749 | $74.76K | Aug 17, 2026 | Exercise of Options Under a Registered Plan |
| Christopher Ryan Sullivan Officer | Aug 17, 2026 | 70,709 | $1.39M | Aug 17, 2026 | Exercise of Stock Options |
| Mittie Doyle Officer | Aug 17, 2026 | 5,037 | $98.67K | Aug 17, 2026 | Exercise of Stock Options |
| Jennifer Riley Officer | Aug 11, 2026 | 2,655 | $52.01K | Aug 11, 2026 | Shares Purchased Through Employee Stock Purchase Plan |
| Mittie Doyle Officer | Aug 10, 2026 | 679 | $12.44K | Aug 10, 2026 | Exercise of Stock Options |
| Jonathan Goldman Director | Jun 2, 2026 | 42,833 | $616.23K | Jun 2, 2026 | Exercise of options under a registered plan |
| Christopher Ryan Sullivan Officer | May 7, 2026 | 18,606 | $405.80K | May 7, 2026 | Exercise of Stock Options |
| Mitchell Chan Director | May 6, 2026 | 3,167 | $51.50K | May 6, 2026 | Restricted Stock Units |
| Paul Varki Officer | May 6, 2026 | 92,771 | $1.51M | May 6, 2026 | Exercise of Stock Options |
| Christopher Ryan Sullivan Officer | May 6, 2026 | 47,000 | $764.22K | May 6, 2026 | Exercise of Stock Options |
| Mittie Doyle Officer | May 6, 2026 | 54,508 | $886.30K | May 6, 2026 | Exercise of Stock Options |
| Christopher Ryan Sullivan Officer | Apr 29, 2026 | 16,915 | $217.53K | Apr 29, 2026 | Restricted Stock Units |
| Mittie Doyle Officer | Apr 6, 2026 | 65,800 | $1.17M | Apr 6, 2026 | Exercise of Stock Options |
| Christopher Ryan Sullivan Officer | Apr 1, 2026 | 15,959 | $238.27K | Apr 1, 2026 | Restricted Stock Units |
See a number that looks wrong?